{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:31:05Z","timestamp":1787923865195,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01HS029501"],"award-info":[{"award-number":["R01HS029501"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107378","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:02:08Z","timestamp":1783353728000},"page":"107378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DIscontinuation of disease-modifying therapies in older adults with multiple sclerosis"],"prefix":"10.1016","volume":"113","author":[{"given":"Jieni","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107378_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: does it matter?","volume":"36","author":"Andersen","year":"1995","journal-title":"J. Health Soc. Behav."},{"issue":"4","key":"10.1016\/j.msard.2026.107378_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1352458520923945","article-title":"Frailty in ageing persons with multiple sclerosis","volume":"27","author":"Ayrignac","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107378_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104603","article-title":"Frailty and relapse activity in multiple sclerosis: a longitudinal observation","volume":"72","author":"Baione","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107378_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1277477","article-title":"Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis","volume":"14","author":"Blok","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107378_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.829331","article-title":"Late-onset MS: disease course and safety-efficacy of DMTS","volume":"13","author":"Buscarinu","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107378_bib7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","article-title":"The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses","volume":"9","author":"Claflin","year":"2018","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107378_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107378_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/14737175.2017.1340831","article-title":"To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question","volume":"17","author":"D'Amico","year":"2017","journal-title":"Expert. Rev. NeurOther"},{"issue":"18","key":"10.1016\/j.msard.2026.107378_bib10","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1503\/cmaj.131873","article-title":"Deprescribing for older patients","volume":"186","author":"Frank","year":"2014","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.msard.2026.107378_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107378_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"9","key":"10.1016\/j.msard.2026.107378_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11910-024-01355-w","article-title":"De-escalation and discontinuation of disease-modifying therapies in multiple sclerosis","volume":"24","author":"Gross","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"5","key":"10.1016\/j.msard.2026.107378_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107378_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12877-021-02208-8","article-title":"A systematic review of the evidence for deprescribing interventions among older people living with frailty","volume":"21","author":"Ibrahim","year":"2021","journal-title":"BMC. Geriatr."},{"issue":"12","key":"10.1016\/j.msard.2026.107378_bib16","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1007\/s00415-020-10029-9","article-title":"Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease inactivity","volume":"267","author":"Kaminsky","year":"2020","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107378_bib17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study","volume":"74","author":"Kim","year":"2019","journal-title":"J. Gerontol. Biol. Sci. Med. Sci."},{"issue":"7","key":"10.1016\/j.msard.2026.107378_bib18","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/rheumatology\/keac665","article-title":"Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis","volume":"62","author":"Letarouilly","year":"2023","journal-title":"Rheumatol. (Oxford)"},{"key":"10.1016\/j.msard.2026.107378_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/13524585251368687","article-title":"Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021","volume":"31","author":"Li","year":"2025","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2026.107378_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40263-018-0541-5","article-title":"Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"32","author":"Lucchetta","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2026.107378_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"Macaron","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107378_bib22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fneur.2020.00851","article-title":"Comorbidity in Multiple sclerosis","volume":"11","author":"Magyari","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107378_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.msard.2026.107378_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107378_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping disease-modifying treatments in Multiple sclerosis: a systematic review and meta-analysis of real-world studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2026.107378_bib26","author":"Pyenson"},{"issue":"17","key":"10.1016\/j.msard.2026.107378_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107378_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107612","article-title":"Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression","volume":"225","author":"Salavisa","year":"2023","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"3","key":"10.1016\/j.msard.2026.107378_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107378_bib30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ene.12690","article-title":"Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials","volume":"22","author":"Signori","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107378_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-med-070822-101947","article-title":"Polypharmacy and deprescribing in older adults","volume":"75","author":"Thompson","year":"2024","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.107378_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107378_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on multiple sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107378_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/XCS.0000000000000429","article-title":"Social vulnerability and emergency general surgery among Medicare beneficiaries","volume":"236","author":"Zhang","year":"2023","journal-title":"J. Am. Coll. Surg."},{"issue":"2","key":"10.1016\/j.msard.2026.107378_bib35","article-title":"The high cost-related medication non-adherence rate among Medicare-Medicaid dual-eligible diabetes patients","volume":"2","author":"Zhang","year":"2016","journal-title":"J. Health Med. Econ."},{"issue":"3","key":"10.1016\/j.msard.2026.107378_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WCO.0000000000001272","article-title":"Treatment discontinuation in older people with multiple sclerosis","volume":"37","author":"Zhu","year":"2024","journal-title":"Curr. Opin. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:51:30Z","timestamp":1787921490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S2211034826004141"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107378","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DIscontinuation of disease-modifying therapies in older adults with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107378"}}